April 28, 2017 10:48 AM EDTUpdated May 1, 07:34 AM

Novartis bags FDA OK for Rydapt, adding a new chemo combo drug for AML

John Carroll

Editor & Founder

Novartis has picked up a new drug approval, this time for Rydapt (midostaurin, PKC412) for newly diagnosed cases of acute myeloid leukemia among patients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis bags FDA OK for Rydapt, adding a new chemo combo drug for AML

John Carroll

Editor & Founder

Sign up to read this article for free.

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Outlook's shares crash as wet AMD drug flunks Phase 3 test

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

No­var­tis bags FDA OK for Ry­dapt, adding a new chemo com­bo drug for AML

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Novartis bags FDA OK for Rydapt, adding a new chemo combo drug for AML

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Outlook's shares crash as wet AMD drug flunks Phase 3 test

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M